前往化源商城

品牌现货直购
供应商:我要出现这里




  • 湖北巨胜科技有限公司
  • 湖北省 省直辖县级行政单位 天门市
  • 产品名:水杨酸钠
  • 纯度:99.0%
  • 规格:500g/1kg/25kg/200kg
  • 联系人:徐女士
    QQ交流
    1466039 复制
    QQ交流二维码
    微信交流
    15107166762 复制
    微信交流二维码
  • 联系电话:15107166762


  • 中山星瑞化工有限公司
  • 广东省 中山市 中山火炬高技术产业开发区
  • 产品名:水杨酸钠
  • 纯度:99.0%
  • 规格:25kg
  • 联系人:王经理
    QQ交流
    3096638339 复制
    QQ交流二维码
    微信交流
    13380886747 复制
    微信交流二维码
  • 联系电话:13380886747


查看所有供应商和价格请点击:

54-21-7生产厂家

54-21-7价格

54-21-7

54-21-7结构式
54-21-7结构式

化源商城直购

中文名 水杨酸钠
英文名 Sodium salicylate
中文别名 水杨酸钠 250G 大茂
柳酸钠/邻羟基苯甲酸钠/2-羟基苯甲酸单钠盐/杨酸钠
美沙拉秦杂质17钠盐(美沙拉秦杂质O钠盐)
水杨酸钠/A1A
柳酸钠
杨酸钠
水杨酸钠 /250克/15元
水杨酸钠标准品
美沙拉嗪杂质H钠盐
2-羟基苯甲酸钠
水杨酸钠Sodium Salicylate
水杨酸 钠盐
2-羟基苯甲酸 钠盐
2-羟基苯甲酸单钠盐
水杨酸钠对照品
水扬酸钠
抑制剂Sodium salicylate
水杨酸钠 现货
水杨酸钠 G
水杨酸钠,10 MM DMSO 溶液
美沙拉嗪杂质17钠盐(美沙拉嗪杂质H钠盐)
邻羟基苯甲酸钠
柳酸鈉
水杨酸钠/邻羟基苯甲酸钠
水杨酸钠 SALICYLIC ACID SODIUM SALT
水杨酸钠溶液, 100PPM
bkmamlab 水杨酸钠g/瓶
水杨酸
柳酸钠,2-羟基苯甲酸单钠盐,邻羟基苯甲酸钠,杨酸钠
水楊酸鈉
bkmamlab 水杨酸钠()g/瓶
水杨酸钠, (NT)
水杨酸钠(
水杨酸钠溶液
Sodium salicylate BP2008 99。白色粉末
呱西替柳杂质
水杨酸钠 标准品
水杨酸钠,FOR ANALYSIS
英文别名 Sodium sallicylate
SODIUM SALICYLATE, REAGENTPLUS TM, >=
aroall
Sodium Salicylate 2-Hydroxybenzoic acid monosodium salt Sodium o-hydroxybenzoate
SODIUM SALICYLATE CRYSTALLIZED
2-Hydroxybenzoic acid anion
kerasalicyl
dall
sodium salicylate
ardall
SODIUMSALICYLATE,CRYSTAL
magsalyl
MFCD00002440
Sodium salicylate, 100ppm
Glutosalyl
Salicylic acid, sodiuM salt
SODIUM SALICYLATE, PH EUR
Sodium salicylate Vetec(TM) ade
SALICYLATE
SALICYLIC ACID, NA
Sdium salicylate
Idocyll novum
Camporisin
SodiumSalicylaturified
Sodium Salicylate, Crystal
SodiumSalicylate
SODIUM SALICYLATE, REAGENTPLUS TM, >
SODIUM SALICYLATE FOR ANALYSIS EMSURE
nadisal
SALICYLIC ACID SODIUM SALT
NASAL
salicylic acid sodium salt
enterosalicyl
salisod
SODIUM 2-HYDROXYBENZOATE
SALICYCLIC ACID, SODIUM SALT
Sodium salicylate,2-Hydroxybenzoic acid sodium salt, Salicylic acid sodium salt
Sodium salicylate . p.a., Reag. Ph. Eur., (calc. to the dried substance)
SODIUM SALICYLATE, REAGENTPLUS, >=
sodium 2-hydroxybenzoate
Sodium salicylate BP98
NATRII SALICYLAS
2-Hydroxybenzoic acid sodium salt, Salicylic acid sodium salt
alysine
enterosalil
clin
oall
2-Hydroxybenzoic acid sodium salt, Natrii salicylas, Salicylic acid sodium salt
kerosal
Benzoicacid,2-hydroxy-,monosodiumsalt
SODIUM SALICYLATE ADE
SODIUM SALICYLATE R. G., REAG. PH. EUR
Sodium Salicylate/Salicylic acid sodium salt
salicylic acid sodium
EINECS 200-198-0
2-Hydroxybenzoate
idocylnovum
diuretin
salicylic acid monosodium salt
Salicylic acid anion
描述 Sodium Salicylate 抑制 COX-2 活性,抑制作用与转录因子 (NF-κB) 激活无关。
相关类别
靶点

COX-2

Autophagy

体外研究 水杨酸钠是一种有效的COX-2活性抑制剂,其浓度远低于抑制NF-κB(20 mg/mL)活化所需的浓度。当与白细胞介素1β一起加入24小时时,水杨酸钠抑制前列腺素E2释放,IC50值为5μg/ mL,这种作用不依赖于NF-κB活化或COX-2转录或翻译。在0,1或10μM外源花生四烯酸存在下,急性(30分钟)水杨酸钠也引起浓度依赖性的COX-2活性抑制。相反,当外源花生四烯酸增加至30μM时,水杨酸钠是一种非常弱的COX-2活性抑制剂,IC50>100μg/ mL。当与IL-1β一起加入24小时时,水杨酸钠引起PGE 2释放的浓度依赖性抑制,表观IC 50值为约5μg/ mL。在暴露30分钟后测试水杨酸钠直接抑制A549细胞中COX-2活性的能力,然后加入不同浓度的外源花生四烯酸(1,10和30μM)。在没有添加花生四烯酸的情况下或在1或10μM外源底物存在下,水杨酸钠引起COX-2活性的浓度依赖性抑制,表观IC 50值为约5μg/ mL。然而,当使用30μM花生四烯酸进行相同的实验时,水杨酸钠是COX-2活性的无效抑制剂,表观IC50值大于100μg/ mL,并且实现最大抑制小于50%[ 1]。
体内研究 在C57Bl/6 DIO小鼠中,水杨酸盐降低空腹和餐后血浆葡萄糖水平。此外,在C57Bl/6DIO小鼠中水杨酸盐处理后存在降低血浆甘油三酯水平的趋势(P = 0.059)。水杨酸盐显着降低C57Bl/6 DIO小鼠网膜脂肪组织中的11β-HSD1 mRNA,其在肠系膜脂肪中具有相似的趋势(P = 0.057)。在C57Bl/6 DIO小鼠的肠系膜脂肪中,水杨酸盐还降低了11β-HSD1酶活性[2]。
激酶实验 将人纯化的COX-2和辅因子谷胱甘肽(5mM),肾上腺素(5mM)和血红素(1μM)溶解于50mM Tris缓冲液(pH7.5)中。首先将血红素溶于100mM的1M NaOH浓缩原液中,然后在Tris缓冲液中进一步稀释。酶反应在96孔板的各孔中进行,最终反应体积为200μL。向板中加入不同浓度的水杨酸钠,然后加入10单位的酶(180μL)。将板在37°温育30分钟,然后再加入花生四烯酸(10nM至30μM)15分钟。通过将板加热至100℃持续5分钟来终止反应。然后将96孔板以10,000×g离心10分钟,取出适当的样品并加入放射免疫测定[1]。
细胞实验 为了评估水杨酸钠在诱导后对COX-2活性的直接影响,首先用IL-1β处理A549细胞24小时,并用含有不同浓度的水杨酸钠的DMEM替换培养基(10,100和1000μg/ mL)。将细胞在37℃下孵育30分钟。然后加入花生四烯酸(1-30μM)15分钟,取出培养基用于测量PGE2 [1]。
动物实验 小鼠[2]成年雄性C57Bl / 6小鼠在12周龄。饮食诱导的肥胖C57Bl / 6小鼠(C57B1 / 6DIO)在治疗前给予10周的高脂肪饮食(58%脂肪,12%蔗糖)。在到达(C57Bl / 6 Lean)后1周,高脂肪喂养10周后(C57Bl / 6 DIO)或达到目标体重后给予水杨酸钠(120mg / kg /天)或蒸馏水(载体) (HSD1KO-DIO)通过渗透性微型泵在肩胛骨之间皮下植入4周至n = 8组。
参考文献

[1]. Mitchell JA, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol. 1997 Jun;51(6):907-12.

[2]. Nixon M, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012 Apr;61(4):790-6.

沸点 336.3ºC at 760mmHg
熔点 >300 °C(lit.)
分子式 C7H5NaO3
分子量 160.103
闪点 144.5ºC
精确质量 160.013641
PSA 60.36000
外观性状 白色晶体
折射率 1.435
储存条件

避光保存。

稳定性

1.见光变粉红色。

水溶解性 1000 g/L (20 ºC)
计算化学

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:1

3.氢键受体数量:3

4.可旋转化学键数量:1

5.互变异构体数量:4

6.拓扑分子极性表面积60.4

7.重原子数量:11

8.表面电荷:0

9.复杂度:138

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:2

更多

1. 性状:白色鳞片状结晶或粉末。无气味。见光后变为粉红色。

2. 密度(g/mL,25/4℃): 未确定

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):160~166

5. 沸点(ºC,常压):未确定

6. 沸点(ºC,5.2kPa):未确定

7. 折射率:未确定

8. 闪点(ºC):未确定

9. 比旋光度(º):未确定

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:易溶于水、 乙醇、 甘油。几乎不溶于醚、 氯仿和苯。1g产品溶于0.9ml水、9.2ml乙醇、4ml甘油。水溶液呈微酸性,pH为5~6。

第一部分:化学品名称
化学品中文名称: 水杨酸钠;邻羟基苯甲酸钠
化学品英文名称: Sodium salicylate;Sodium o-hydroxybenzoate
中文俗名或商品名:
Synonyms:
CAS No.: 54-21-7
分子式: C7H5NaO3
分子量: 160.11
第二部分:成分/组成信息
纯化学品混合物
化学品名称:水杨酸钠;邻羟基苯甲酸钠
有害物成分 含量 CAS No.
第三部分:危险性概述
危险性类别:
侵入途径: 吸入 食入 经皮吸收
健康危害: 对眼睛、皮肤、粘膜和上呼吸道有刺激作用。刺激消化道,引起食欲不振、恶心、呕吐,严重时可致消化道出血,并能诱发和加重胃溃疡;也可引起头痛、眩晕、耳鸣、视力减退、过敏反应等。
环境危害:
燃爆危险: 本品可燃,具刺激性。
第四部分:急救措施
皮肤接触: 用肥皂水及清水彻底冲洗。就医。
眼睛接触: 拉开眼睑,用流动清水冲洗15分钟。就医。
吸入: 脱离现场至空气新鲜处。就医。
食入: 误服者,饮适量温水,催吐。就医。
第五部分:消防措施
危险特性: 遇明火、高热可燃。受高热分解,放出有毒的烟气。
有害燃烧产物: 一氧化碳、二氧化碳、氧化钠。
灭火方法及灭火剂: 消防人员须佩戴防毒面具、穿全身消防服,在上风向灭火。切勿将水流直接射至熔融物,以免引起严重的流淌火灾或引起剧烈的沸溅。灭火剂:泡沫、二氧化碳、干粉、砂土。
消防员的个体防护:
禁止使用的灭火剂:
闪点(℃):
自燃温度(℃):
爆炸下限[%(V/V)]:
爆炸上限[%(V/V)]:
最小点火能(mJ):
爆燃点:
爆速:
最大燃爆压力(MPa):
建规火险分级:
第六部分:泄漏应急处理
应急处理: 隔离泄漏污染区,周围设警告标志,建议应急处理人员戴好防毒面具,穿化学防护服。用大量水冲洗,经稀释的污水放入废水系统。也可以小心扫起,避免扬尘,收集运至废物处理场所。如大量泄漏,收集回收或无害处理后废弃。
第七部分:操作处置与储存
操作注意事项: 密闭操作,局部排风。防止粉尘释放到车间空气中。操作人员必须经过专门培训,严格遵守操作规程。建议操作人员佩戴自吸过滤式防尘口罩,戴化学安全防护眼镜,穿防毒物渗透工作服,戴橡胶手套。远离火种、热源,工作场所严禁吸烟。使用防爆型的通风系统和设备。避免产生粉尘。避免与氧化剂、碱类接触。配备相应品种和数量的消防器材及泄漏应急处理设备。倒空的容器可能残留有害物。
储存注意事项: 储存于阴凉、通风的库房。远离火种、热源。防止阳光直射。包装密封。应与氧化剂、碱类分开存放,切忌混储。配备相应品种和数量的消防器材。储区应备有合适的材料收容泄漏物。
第八部分:接触控制/个体防护
最高容许浓度: 中 国 MAC:未制订标准前苏联 MAC:未制订标准美国TLV—TWA:未制订标准
监测方法:
工程控制: 密闭操作,局部排风。
呼吸系统防护: 佩戴防尘口罩。空气中浓度较高时,建议佩戴防毒面具。
眼睛防护: 戴化学安全防护眼镜。
身体防护: 穿相应的防护服。
手防护: 戴防化学品手套。
其他防护: 工作后,淋浴更衣。保持良好的卫生习惯。
第九部分:理化特性
外观与性状: 白色鳞片或粉末,无气味,久露光线中变粉红色。
pH:
熔点(℃): 200
沸点(℃):
相对密度(水=1):
相对蒸气密度(空气=1):
饱和蒸气压(kPa):
燃烧热(kJ/mol):
临界温度(℃):
临界压力(MPa):
辛醇/水分配系数的对数值:
闪点(℃):
引燃温度(℃):
爆炸上限%(V/V):
爆炸下限%(V/V):
分子式: C7H5NaO3
分子量: 160.11
蒸发速率:
粘性:
溶解性: 溶于水、甘油,不溶于醚、氯仿、苯。
主要用途: 作解热、镇痛药,分析试剂,防腐剂。
第十部分:稳定性和反应活性
稳定性: 在常温常压下 稳定
禁配物: 强氧化剂、强酸。
避免接触的条件: 光照。
聚合危害: 不能出现
分解产物: 一氧化碳、二氧化碳、氧化钠。
第十一部分:毒理学资料
急性毒性: LD50:1200mg/kg(大鼠经口) LC50:
急性中毒:
慢性中毒:
亚急性和慢性毒性:
刺激性:
致敏性:
致突变性:
致畸性:
致癌性:
第十二部分:生态学资料
生态毒理毒性:
生物降解性:
非生物降解性:
生物富集或生物积累性:
第十三部分:废弃处置
废弃物性质:
废弃处置方法: 建议用焚烧法处置。在能利用的地方重复使用容器或在规定场所掩埋。
废弃注意事项:
第十四部分:运输信息
危险货物编号:
UN编号:
包装标志:
包装类别:
包装方法:
运输注意事项: 储存于阴凉、通风仓间内。远离火种、热源。包装密封。避光保存。应与氧化剂、酸类、食用化工原料分开存放。搬运时轻装轻卸,保持包装完整,防止泄漏。分装和搬运作业要注意个人防护。
RETCS号:
IMDG规则页码:
第十五部分:法规信息
国内化学品安全管理法规: 化学危险物品安全管理条例 (1987年2月17日国务院发布),化学危险物品安全管理条例实施细则 (化劳发[1992] 677号),工作场所安全使用化学品规定 ([1996]劳部发423号)等法规,针对化学危险品的安全使用、生产、储存、运输、装卸等方面均作了相应规定。
国际化学品安全管理法规:
第十六部分:其他信息
参考文献: 1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
填表时间: 年月日
填表部门:
数据审核单位:
修改说明:
其他信息: 6
MSDS修改日期: 年月日

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VO5075000
CHEMICAL NAME :
Salicylic acid, monosodium salt
CAS REGISTRY NUMBER :
54-21-7
LAST UPDATED :
199703
DATA ITEMS CITED :
69
MOLECULAR FORMULA :
C7-H5-O3.Na
MOLECULAR WEIGHT :
160.11
WISWESSER LINE NOTATION :
QVR BQ &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
700 mg/kg
TOXIC EFFECTS :
Behavioral - excitement Behavioral - muscle contraction or spasticity Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1400 mg/kg
TOXIC EFFECTS :
Behavioral - toxic psychosis Lungs, Thorax, or Respiration - respiratory stimulation Skin and Appendages - sweating
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Multiple routes
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
2970 mg/kg/13D
TOXIC EFFECTS :
Behavioral - excitement Gastrointestinal - nausea or vomiting
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
930 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - muscle contraction or spasticity
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
542 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
540 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
550 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
560 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
760 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
450 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
990 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea Lungs, Thorax, or Respiration - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
562 mg/kg
TOXIC EFFECTS :
Behavioral - analgesia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
1700 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
415 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
900 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Cardiac - arrhythmias (including changes in conduction) Behavioral - excitement Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Amphibian - frog
DOSE/DURATION :
250 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2100 mg/kg/7D-C
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
6600 mg/kg/11D-I
TOXIC EFFECTS :
Liver - other changes Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
16350 mg/kg/15W-I
TOXIC EFFECTS :
Behavioral - muscle weakness Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
18200 mg/kg/13W-C
TOXIC EFFECTS :
Liver - other changes Kidney, Ureter, Bladder - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
3360 mg/kg/14D-I
TOXIC EFFECTS :
Behavioral - fluid intake Kidney, Ureter, Bladder - urine volume increased Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
3900 mg/kg/2W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
40 mg/kg
SEX/DURATION :
female 20-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
250 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
250 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
25 mg/kg
SEX/DURATION :
female 20-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
375 mg/kg
SEX/DURATION :
female 8-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
3 gm/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
500 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
849 mg/kg
SEX/DURATION :
female 9-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
150 mg/kg
SEX/DURATION :
female 12-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
300 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - Central Nervous System
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
50 mg/kg
SEX/DURATION :
female 21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
400 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - body wall
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
300 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
600 mg/kg
SEX/DURATION :
female 6-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
400 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
400 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
665 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
4 gm/kg
SEX/DURATION :
female 8-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2 gm/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1500 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8 gm/kg
SEX/DURATION :
female 8-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
400 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
400 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
500 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
500 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
1100 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
125 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
250 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
400 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
125 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
DNA damage
TYPE OF TEST :
Cytogenetic analysis

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
350 mg/kg
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 370,1,1996 *** REVIEWS *** TOXICOLOGY REVIEW PEDIAU Pediatrics. (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1- 1948- Volume(issue)/page/year: 54,342,1974 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New York, NY 10022) V.1- 1946- Volume(issue)/page/year: 38,409,1965 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW 85DJA5 "Malformations Congenitales des Mammiferes," Tuchmann-Duplessis, H., Paris, Masson et Cie, 1971 Volume(issue)/page/year: -,171,1971 TOXICOLOGY REVIEW APSQA7 Acta Paediatrica Scandinavica, Supplement. (Almqvist & Wiksell International, POB 4627, S-11691 Stockholm, Sweden) No. 158-379 1965-91 Volume(issue)/page/year: (211),24,1971 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84407 No. of Facilities: 1892 (estimated) No. of Industries: 6 No. of Occupations: 16 No. of Employees: 16641 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84407 No. of Facilities: 2056 (estimated) No. of Industries: 9 No. of Occupations: 18 No. of Employees: 29395 (estimated) No. of Female Employees: 19141 (estimated)

符号 GHS07
GHS07
信号词 Warning
危害声明 H302-H319
警示性声明 P301 + P312 + P330-P305 + P351 + P338
个人防护装备 dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲) Xn:Harmful
风险声明 (欧洲) R22
安全声明 (欧洲) S26
危险品运输编码 NONH for all modes of transport
WGK德国 1
RTECS号 VO5075000
海关编码 2918211000

1.将水杨酸和碳酸氢钠交叉加入蒸馏水中,温度保持60℃,并保持呈酸性状态,同时加入适量乙二胺四乙酸(EDTA)及保险粉。升温至85℃,反应半小时。将合格的反应液经过滤送入沸腾床,85℃干燥得水杨酸。

2.将水杨酸于50℃下溶解于蒸馏水中,在搅拌下慢慢的用稀氢氧化钠中和至ph值5.4~5.8:

54-21-7 preparation

反应结束后脱色过滤,滤液清亮后,减压浓缩至浆状,冷却,过滤出结晶,干燥后即为成品。

海关编码 2918211000
中文概述 2918211000. 水杨酸、水杨酸钠. 增值税率:17.0%. 退税率:9.0%. 监管条件:无. 最低关税:6.5%. 普通关税:20.0%
申报要素 品名, 成分含量, 用途
Summary 2918211000. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:6.5%. General tariff:20.0%
本网页内容来自不同专业数据源,如对内容有疑义,欢迎联系service1@chemsrc.com。